lifestyle.newsblaze.com

Author: ELI LILLY AND COMPANY

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

April 16, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

April 16, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

April 13, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

April 1, 2026
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

March 31, 2026
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

March 30, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

March 27, 2026
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

March 19, 2026